openPR Logo
Press release

Hyperkalemia Market: Epidemiology, Pipeline, and Key Companies Working in the Market | Ardelyx, AstraZeneca, Vifor Pharma

09-04-2024 05:14 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Hyperkalemia Market

Hyperkalemia Market

DelveInsight has launched a new report on "Hyperkalemia - Market Insights, Epidemiology, and Market Forecast-2034".
DelveInsight's "Hyperkalemia - Market Insights, Epidemiology, and Market Forecast-2034″ report delivers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Download report @ https://www.delveinsight.com/report-store/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Hyperkalemia Market Report:
In 2023, there were approximately 5.8 million diagnosed cases of hyperkalemia across the 7MM (United States, EU5 countries, and Japan). The anticipated rise in cases is driven by several factors, including an aging population, increasing rates of chronic kidney disease and heart failure, greater awareness and diagnosis, as well as lifestyle and dietary changes contributing to higher potassium imbalances.
Among the comorbidities associated with hyperkalemia, hypertension (HTN) represents the largest proportion, with around 4.4 million cases. This high prevalence is likely due to the common use of medications such as renin-angiotensin-aldosterone system (RAAS) inhibitors, which can lead to elevated potassium levels as a side effect.
The hyperkalemia market is significantly influenced by novel potassium binders, particularly LOKELMA and VELTASSA. Both medications have seen substantial adoption for long-term management of hyperkalemia due to their effectiveness. In 2023, LOKELMA held a larger market share, being especially prescribed for chronic management in outpatient settings.
With new therapies expected to gain approval during the forecast period (2024-2034), the hyperkalemia therapeutic market is anticipated to experience a significant growth spurt, driven by a robust compound annual growth rate (CAGR).

Key benefits of the Hyperkalemia market report:
• The hyperkalemia market report covers a descriptive overview and comprehensive insight of the Hyperkalemia Epidemiology and Hyperkalemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
• The Hyperkalemia market report provides insights into the current and emerging therapies.
• Hyperkalemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
• The Hyperkalemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hyperkalemia market.
Got queries? Click here to know more about the Hyperkalemia Market Landscape @ https://www.delveinsight.com/report-store/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hyperkalemia Overview
Hyperkalemia, marked by elevated potassium levels in the blood, poses a significant health risk due to its potential to cause life-threatening cardiac arrhythmias and other serious complications. Although mild cases can be asymptomatic, higher potassium levels or rapid fluctuations can lead to noticeable symptoms. Key risk factors include renal impairment, such as acute kidney injury and advanced chronic kidney disease, as well as defects in potassium excretion mechanisms. In addition to cardiac risks, hyperkalemia is associated with increased mortality, impacts prescribing practices, and can contribute to renal and neurological complications in patients with chronic kidney disease. Thus, vigilant monitoring and effective management are crucial to mitigating these risks.

Diagnosing hyperkalemia involves a comprehensive assessment that includes patient interviews, physical examinations, blood tests, urinalysis, and electrocardiograms. These diagnostic tools help measure potassium levels and identify underlying causes, guiding treatment decisions. Factors such as medical history, medication use, dietary habits, and hormonal imbalances are evaluated. Distinguishing between acute and chronic hyperkalemia, assessing potassium excretion, and interpreting electrocardiogram results can present challenges. Accurate diagnosis is essential for managing hyperkalemia effectively and preventing potentially life-threatening complications.

The treatment strategy for hyperkalemia is multifaceted, addressing both immediate and long-term challenges. Immediate treatments aim to stabilize cardiac function and shift potassium into cells to prevent severe complications. Long-term management focuses on maintaining potassium balance through various mechanisms to ensure sustained control of serum potassium levels. Recent advancements, such as the introduction of LOKELMA and VELTASSA, offer promising options for oral potassium management, reflecting ongoing progress in hyperkalemia treatment. Effective management requires personalized care, continuous monitoring, and regular adjustments to optimize patient outcomes while navigating the complexities of this condition.

Hyperkalemia Market Outlook
Hyperkalemia, which is classified into mild, moderate, and severe forms, requires prompt intervention to prevent serious complications such as cardiac arrhythmias and muscle paralysis, particularly in moderate-to-severe cases. Treatment strategies are tailored based on the onset of symptoms, serum potassium levels, and evidence of toxicity. Acute management focuses on rapidly addressing elevated potassium levels, while long-term treatment involves dietary adjustments and medications, with a low-potassium diet recommended following the acute phase.

Currently, off-label drug use is prevalent due to complications associated with approved treatments, driving pharmaceutical companies to explore innovative research for safer and more effective solutions. The emphasis is on developing new mechanisms of action to meet the needs of patients with chronic or severe hyperkalemia, particularly those on multiple medications, indicating a growing demand for improved therapeutic options.

The outlook for the hyperkalemia market is optimistic, with significant opportunities for innovation and enhanced treatment options. According to DelveInsight, the hyperkalemia market across the 7MM is expected to undergo substantial changes during the study period from 2020 to 2034, reflecting a trend toward better management and outcomes for affected individuals.
Download hyperkalemia market report sample pages @ https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hyperkalemia Pipeline Therapies and Key Companies
• RDX013: Ardelyx
• Lokelma: AstraZeneca
• Veltassa: Vifor Pharma
Hyperkalemia Epidemiology Insights
In 2023, the total number of diagnosed prevalent cases of hyperkalemia across the 7MM (United States, EU4 countries, and Japan) was estimated to be approximately 5.8 million. This figure is projected to grow significantly by 2034, reflecting a notable compound annual growth rate (CAGR) during the study period from 2020 to 2034.
Within the 7MM, the United States alone accounted for about 80% of the diagnosed prevalent cases in 2023, and this proportion is expected to increase further by 2034.
Among the EU4 countries and the United Kingdom, Germany reported the highest number of diagnosed prevalent cases of hyperkalemia, with approximately 0.21 million cases in 2023. Conversely, Spain had the lowest number, with around 16,000 cases during the same year.
In Japan, the diagnosed prevalent cases of hyperkalemia in 2023 were estimated at approximately 0.7 million, with expectations for this number to evolve throughout the study period.
DelveInsight's epidemiology model indicates that hyperkalemia shows a male predominance across the 7MM, with approximately 2.5 million cases in males and 2.1 million cases in females in the United States in 2023.
The age-specific distribution of hyperkalemia cases reveals that the majority are in the 18-64 years age group, followed by those aged 65-79 years. The least number of cases are observed in the ≥80 age group.
Severity-specific data further categorizes diagnosed prevalent cases into mild, moderate, and severe. The analysis suggests that mild hyperkalemia cases are more common than moderate and severe cases in the United States.
Request for a sample copy @ https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hyperkalemia Patient Share (%) Overview at a Glance
5. Hyperkalemia Market Overview at a Glance
6. Hyperkalemia Disease Background and Overview
7. Hyperkalemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hyperkalemia
9. Hyperkalemia Current Treatment and Medical Practices
10. Unmet Needs
11. Hyperkalemia Emerging Therapies
12. Hyperkalemia Market Outlook
13. Country-Wise Hyperkalemia Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Hyperkalemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Hyperkalemia Market Outlook 2034 @ https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports by DelveInsight:
● Adalimumab Biosimilar Market
● Arbovirus Infection Market
● Artificial Pancreas Device System Market
● Dental Equipment Market
● Gluten Sensitivity Market
● Hypothyroidism Market
● Inflammatory Bowel Disease Market
● Mayus Kinase Jak Inhibitors Market
● Mild Dry Eye Market
● Mucopolysaccharidosis Market
● Oncolytic Virus Cancer Therapy Market
● Pyoderma Gangrenosum Market
● Transdermal Drug Delivery Devices Market
● Intrathecal Pumps Market
● Hedgehog Pathway Inhibitors Market
● Yellow Fever Market
● Laryngeal Cancer Market
● Female Infertility Market
● Gender Dysphoria Market
● Chronic Brain Damage Market
● Spain Healthcare Outlook Market
● Malignant Fibrous Histiocytoma Market

Contact Us:
Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperkalemia Market: Epidemiology, Pipeline, and Key Companies Working in the Market | Ardelyx, AstraZeneca, Vifor Pharma here

News-ID: 3645570 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Hyperkalemia

Hyperkalemia Treatment Market Moving in the Right Direction: AstraZeneca, Ardely …
The latest study released on the Global Hyperkalemia Treatment Market by HTF MI Research evaluates market size, trend, and forecast to 2030. The Hyperkalemia Treatment market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key Players
Hyperkalemia Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031 …
Global Hyperkalemia Drugs Market to Surpass US$ Million Mark by 2030, Reveals New Market Report The hyperkalemia drugs market, valued at US$ million in 2023, is anticipated to achieve a significant milestone, reaching US$ million by 2030, showcasing a robust CAGR growth during the forecast period of 2024-2031. Hyperkalemia, characterized by elevated levels of potassium in the bloodstream, poses severe health risks including life-threatening cardiac arrhythmias and paralysis, primarily attributed to impaired
Global Hyperkalemia Treatment Market Research Report 2023
Hyperkalemia Treatment Market Size The global Hyperkalemia Treatment market was valued at US$ 540 million in 2022 and is anticipated to reach US$ 2068.8 million by 2029, witnessing a CAGR of 20.9% during the forecast period 2023-2029. Hyperkalemia Treatment Market Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating
Hyperkalemia Market to Reach US$ 2,320.5 Million by 2033 | IMARC Group
The newly published report by IMARC Group, titled "Hyperkalemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the hyperkalemia market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements
Hyperkalemia Treatment Market Size, Share, Industry, Forecast to 2030
The Hyperkalemia Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Hyperkalemia Treatment market. This report explores all the key factors affecting the growth of the global Hyperkalemia Treatment market, including
Global Hyperkalemia Supplement Market, Size, Share, Analysis Report & Forecast t …
The global hyperkalemia treatment market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing chronic diseases such as acute hyperkalemia and chronic hyperkalemia due to other ailments such as diabetes, consumption of high potassium diets, and many other things. As per the National Kidney Foundation, more than 37 million people in the United States have